中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.027 seconds)

    HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS
    1.
    发明申请
    HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS 审中-公开
    具有对肌肉受体的亲和性的杂环化合物

    公开(公告)号：WO2008129054A3

    公开(公告)日：2009-02-05

    申请号：PCT/EP2008054897

    申请日：2008-04-23

    Applicant: SOLVAY PHARM BV ,  STOIT AXEL ,  COOLEN HEIN K A C ,  KRUSE CORNELIS G ,  TERWEL LOUISE HEIR OF REINDERS

    Inventor： STOIT AXEL ,  COOLEN HEIN K A C ,  KRUSE CORNELIS G ,  TERWEL LOUISE HEIR OF REINDERS

    IPC: C07D401/04 ,  A61K31/439 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/28 ,  C07D401/14 ,  C07D413/04 ,  C07D453/02 ,  C07D471/08

    CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D453/02 ,  C07D471/08

    Abstract: The present invention relates to heterocyclic compounds of the formula (I) wherein - the heterocycle comprises two double bonds which may be present at several positions, represented by the dashed lines ( -- ); - the heterocycle contains two heteroatoms, - W being N or NH; - Y being CH, O or NH, wherein if Y is O, X1 is CH and X2 is the residue C-Z-R2 or C-R3, wherein Z is NH, O, or S; and if Y is CH or NH, one of X1 and X2 is CH or N, the other being the residue C-Z-R2 or C-R3, wherein Z is NH or S; - R1 is selected from the structures (a), (b) and (c): - R2 is selected from (C1-C10)alkyl, (C2-C10)alkenyl and (C2-C10)alkynyl, optionally independently substituted with one or more substituents selected from halogen, hydroxy, cyano, oxo, (C1-C6)alkoxy, (C1-C6)alkylthio, (C1-C6)alkenyloxy, (C1-C6)alkenylthio, (C1-C4)alkoxy(C1-C4)alkoxy, (C5-C7)cycloalkyl, a 5-membered unsaturated heterocycle (optionally substituted with halogen), phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; or - R2 is an unbranched (C2-C8)alkyl substituted at the Za-symbol of a group with the formula (Ia) wherein if X1 is CH or N1 X1 is CH or N and X2a is C-Za-, or if X1 is C-Z-R2, X1a is C-Za- and X2a is CH or N; and the symbols Wa, Ya and Za and the substituent R1a have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1 a representing identical symbols and substituents, respectively, as the symbols W, Y and Z and the substituent R1 in the other part of the structure of formula (I); - R3 is selected from (C4-C10) alkyl, (C2-C10) alkenyl and (C2-C10) alkynyl, optionally independently substituted with one or more substituents selected from halogen, hydroxy, cyano, (C1C6) alkoxy, (C1C6) alkylthio, (C1C6)alkenyloxy, (C1C6) alkenylthio, (C1-C4) alkoxy (C1-C4) alkoxy, (C5-C7) cycloalkyl, a 5-membered unsaturated heterocycle optionally substituted with halogen, phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to muscarinic receptors and may be used in the treatment, alleviation or prevention of muscarinic receptor mediated diseases and conditions.

    Abstract translation: 本发明涉及式（I）的杂环化合物，其中 - 杂环包含两个双键，其可以存在于由虚线（ - ）表示的几个位置。 - 杂环含有两个杂原子，-W为N或NH; - Y是CH，O或NH，其中如果Y是O，则X1是CH，X2是残基C-Z-R2或C-R3，其中Z是NH，O或S; 并且如果Y是CH或NH，则X1和X2之一是CH或N，另一个是残基C-Z-R2或C-R3，其中Z是NH或S; -R 1选自（C 1 -C 10）烷基，（C 2 -C 10）烯基和（C 2 -C 10）炔基，任选独立地被一个 （C1-C6）烷氧基，（C1-C6）烷氧基，（C1-C6）烯硫基，（C1-C4）烷氧基（C1- C4烷氧基，（C5-C7）环烷基，5元不饱和杂环（任选被卤素取代），苯基，苯氧基和苯硫基，其中苯基任选被卤素取代; 或 - R 2是在具有式（Ia）的基团的Za符号取代的未支化的（C 2 -C 8）烷基，其中如果X 1是CH或N 1是CH或N 1且X 2是C a Z a，或者如果X 1 是CZ-R2，X1a是C-Za，X2a是CH或N; 并且符号Wa，Ya和Za以及取代基R 1a具有与前面对符号W，Y和Z以及取代基R所定义的相同的含义，并且不是独立地选择，每个符号Wa，Ya和Za以及取代基 R1a分别表示与式（I）结构的另一部分中的符号W，Y和Z以及取代基R 1相同的符号和取代基; 羟基，氰基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷基，（C 2 -C 10） 烷基硫基，（C1C6）烯氧基，（C1C6）烯基硫代，（C1-C4）烷氧基（C1-C4）烷氧基，（C5-C7）环烷基，任选被卤素，苯基，苯氧基和苯硫基取代的5元不饱和杂环，其中 苯基任选被卤素取代; 或其药学上可接受的盐，溶剂合物或水合物。 本发明的化合物对毒蕈碱受体具有亲和力，可用于治疗，缓解或预防毒蕈碱受体介导的疾病和病症。

    N-OXIDES OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AS PRODRUGS
    4.
    发明申请
    N-OXIDES OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AS PRODRUGS 审中-公开
    芬太尼氧化物和邻苯二甲酸氧氟沙星作为PRODRUGS

    公开(公告)号：WO2009000797A1

    公开(公告)日：2008-12-31

    申请号：PCT/EP2008/057939

    申请日：2008-06-23

    Applicant: SOLVAY PHARMACEUTICALS B.V. ,  TURSKI, Lechoslaw A. ,  STOIT, Axel ,  KRUSE, Cornelis G. ,  VADER, Sander ,  TULP, Martinus Th.M.

    Inventor： TURSKI, Lechoslaw A. ,  STOIT, Axel ,  KRUSE, Cornelis G. ,  VADER, Sander ,  TULP, Martinus Th.M.

    IPC: C07C291/04 ,  A61K31/135 ,  A61P25/24

    CPC classification number: C07C291/04

    Abstract: The invention concerns venlafaxine-N-oxide and O-desmethylvenlafaxine-N-oxide as prodrugs of venlafaxine and its major (active) metabolite O-desmethylvenlafaxine respectively, to pharmaceutical compositions containing these N-oxides, to methods for preparing them, and methods for preparing compositions. The invention relates to N-oxide, having formula (1), wherein R 1 is H or CH 3 , and tautomers, stereoisomers, hydrates and solvates thereof. The invention also relates to the uses of the N-oxides and compositions, particularly for the manufacture of medicaments useful in the treatment of affections or diseases effectively treatable - albeit with side effects - with venlafaxine.

    Abstract translation: 本发明涉及文拉法辛-N-氧化物和O-去甲基文拉法辛-N-氧化物作为文拉法辛及其主要（活性）代谢物O-去甲基文拉法辛的前药，含有这些N-氧化物的药物组合物，及其制备方法 制备组合物。 本发明涉及具有式（1）的N-氧化物，其中R 1是H或CH 3，以及互变异构体，立体异构体，水合物和溶剂化物。 本发明还涉及N-氧化物和组合物的用途，特别是用于制备可用于治疗与文拉法辛有效治疗的感染或疾病（尽管有副作用）的药物。

    HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS
    5.
    发明申请
    HETEROCYCLIC COMPOUNDS WITH AFFINITY TO MUSCARINIC RECEPTORS 审中-公开
    具有对肌肉受体的亲和性的杂环化合物

    公开(公告)号：WO2008129054A2

    公开(公告)日：2008-10-30

    申请号：PCT/EP2008/054897

    申请日：2008-04-23

    Applicant: SOLVAY PHARMACEUTICALS B.V. ,  STOIT, Axel ,  COOLEN, Hein K.A.C. ,  KRUSE, Cornelis G. ,  TERWEL, Louise, heir of REINDERS, Jan H. (deceased)

    Inventor： STOIT, Axel ,  COOLEN, Hein K.A.C. ,  KRUSE, Cornelis G. ,  TERWEL, Louise, heir of REINDERS, Jan H. (deceased)

    IPC: C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D471/08 ,  A61K31/4439 ,  A61K31/4427 ,  A61K31/439 ,  A61P25/28 ,  C07D453/02

    CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D413/04 ,  C07D453/02 ,  C07D471/08

    Abstract: The present invention relates to heterocyclic compounds of the formula (I) wherein - the heterocycle comprises two double bonds which may be present at several positions, represented by the dashed lines ( -- ); - the heterocycle contains two heteroatoms, - W being N or NH; - Y being CH, O or NH, wherein if Y is O, X 1 is CH and X 2 is the residue C-Z-R2 or C-R3, wherein Z is NH, O, or S; and if Y is CH or NH, one of X 1 and X 2 is CH or N, the other being the residue C-Z-R2 or C-R3, wherein Z is NH or S; - R1 is selected from the structures (a), (b) and (c): - R2 is selected from (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents selected from halogen, hydroxy, cyano, oxo, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle (optionally substituted with halogen), phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; or - R2 is an unbranched (C 2 -C 8 )alkyl substituted at the Za-symbol of a group with the formula (Ia) wherein if X 1 is CH or N 1 X 1 is CH or N and X 2 a is C-Za-, or if X 1 is C-Z-R2, X 1 a is C-Za- and X 2 a is CH or N; and the symbols Wa, Ya and Za and the substituent R1a have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1 a representing identical symbols and substituents, respectively, as the symbols W, Y and Z and the substituent R1 in the other part of the structure of formula (I); - R3 is selected from (C 4 -C 10 ) alkyl, (C 2 -C 10 ) alkenyl and (C 2 -C 10 ) alkynyl, optionally independently substituted with one or more substituents selected from halogen, hydroxy, cyano, (C 1 C 6 ) alkoxy, (C 1 C 6 ) alkylthio, (C 1 C 6 )alkenyloxy, (C 1 C 6 ) alkenylthio, (C 1 -C 4 ) alkoxy (C 1 -C 4 ) alkoxy, (C 5 -C 7 ) cycloalkyl, a 5-membered unsaturated heterocycle optionally substituted with halogen, phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to muscarinic receptors and may be used in the treatment, alleviation or prevention of muscarinic receptor mediated diseases and conditions.

    Abstract translation: 本发明涉及式（I）的杂环化合物，其中 - 杂环包含两个双键，其可以存在于由虚线（ - ）表示的几个位置。 - 杂环含有两个杂原子，-W为N或NH; - Y是CH，O或NH，其中如果Y是O，则X 1是CH且X 2是残基CZ-R2或C-R3，其中Z是 NH，O或S; 并且如果Y是CH或NH，则X 1和X 2中的一个是CH或N，另一个是残基CZ-R2或C-R3，其中Z是 NH或S; - R 1选自结构（a），（b）和（c）：-R 2选自（C 1 -C 10）烷基，（C 1 -C 10） （C 2 -C 10 -C 10）链烯基和（C 2 -C 10 -C 10）炔基，任选地独立地被一个或多个 取代基选自卤素，羟基，氰基，氧代，（C 1 -C 6 - ）烷氧基，（C 1 -C 6 - （C 1 -C 6 -C 6）烷氧基，（C 1 -C 6）烷硫基，（C 1 -C 6 -C 6）烷氧基，（C 1 -C 6 - ）链烯硫基，（C 1 -C 4 -C 4）烷氧基（C 1 -C 4）烷氧基，（C 5元不饱和杂环（任选被卤素取代），苯基，苯氧基和苯硫基，其中苯基任选被卤素取代; 或 - R 2是在具有式（Ia）的基团的Za符号处被取代的未支化的（C 2 -C 8 -C 8）烷基，其中如果X 1 CH或N 1 X 1是CH或N，X 2是C-Z a，或者如果X < A 1是CZ-R 2，X 1 a是C 1 -C 8，X 2是CH或N; 并且符号Wa，Ya和Za以及取代基R 1a具有与前面对符号W，Y和Z以及取代基R所定义的相同的含义，并且不是独立地选择，每个符号Wa，Ya和Za以及取代基 R1a分别表示与式（I）结构的另一部分中的符号W，Y和Z以及取代基R 1相同的符号和取代基; R 3选自（C 1 -C 10 -C 10）烷基，（C 2 -C 10 -C 10）链烯基 （C 1 -C 10）炔基，任选独立地被一个或多个选自卤素，羟基，氰基，（C 1 -C 10） （C 1 -C 6）烷硫基，（C 1 -C 6）烷氧基，（C 1 -C 6）烷硫基，（C 1 -C 6） （C 1 -C 6）链烯硫基，（C 1 -C 4 -C 4）烷氧基，（C 1 -C 6）烷硫基，（C 1 -C 6） （C 1 -C 4 - ）烷氧基，（C 5 -C 7 -C 7）环烷基，5元环 任选被卤素，苯基，苯氧基和苯硫基取代的不饱和杂环，其中苯基任选被卤素取代; 或其药学上可接受的盐，溶剂合物或水合物。 本发明的化合物对毒蕈碱受体具有亲和力，可用于治疗，缓解或预防毒蕈碱受体介导的疾病和病症。

    SILDENAFIL N-OXIDE AS PRODRUG
    6.
    发明申请
    SILDENAFIL N-OXIDE AS PRODRUG 审中-公开
    SILDENAFIL N-OXIDE作为PRODRUG

    公开(公告)号：WO2009000798A1

    公开(公告)日：2008-12-31

    申请号：PCT/EP2008/057940

    申请日：2008-06-23

    Applicant: SOLVAY PHARMACEUTICALS B.V. ,  TURSKI, Lechoslaw A. ,  STOIT, Axel ,  KRUSE, Cornelis, G. ,  VADER, Sander ,  TULP, Martinus Th., M.

    Inventor： TURSKI, Lechoslaw A. ,  STOIT, Axel ,  KRUSE, Cornelis, G. ,  VADER, Sander ,  TULP, Martinus Th., M.

    IPC: C07D487/04 ,  A61P15/10 ,  A61K31/519 ,  A61P11/00

    CPC classification number: C07D487/04

    Abstract: The invention concerns sildenafil N-oxide as prodrug, to pharmaceutical compositions containing this compound, to methods for preparing it, and methods for preparing compositions. The invention relates to 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methyl-4-oxido-piperazine having formula (1 A ) and pharmacologically acceptable salts, hydrates and solvates thereof. The invention also relates to uses of the compound, and compositions containing it, particularly for the manufacture of medicaments useful in the treatment of affections or diseases effectively treatable - albeit with side effects - with sildenafil.

    Abstract translation: 本发明涉及西地那非N-氧化物作为前药，含有该化合物的药物组合物，其制备方法和制备组合物的方法。 本发明涉及1 - [[3-（6,7-二氢-1-甲基-7-氧代-3-丙基-1H-吡唑并[4,3-d]嘧啶-5-基）-4-乙氧基苯基] 磺酰基] -4-甲基-4-氧代 - 哌嗪及其药理学上可接受的盐，水合物和溶剂化物。 本发明还涉及该化合物和含有它的组合物的用途，特别是用于制备可用于治疗感染或有效治疗的疾病的药物 - 尽管有副作用 - 西地那非。

    (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS
    10.
    发明申请
    (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS 审中-公开
    （THIO）吗啉衍生物作为S1P调节剂

    公开(公告)号：WO2011023795A1

    公开(公告)日：2011-03-03

    申请号：PCT/EP2010/062552

    申请日：2010-08-27

    Applicant: ABBOTT HEALTHCARE PRODUCTS B.V. ,  IWEMA BAKKER, Wouter, I. ,  COOLEN, Hein K.A.C. ,  MONS, Harmen ,  STOIT, Axel ,  RONKEN, Eric ,  KAM, VAN DER, Elizabeth ,  FRANKENA, Jurjen

    Inventor： IWEMA BAKKER, Wouter, I. ,  COOLEN, Hein K.A.C. ,  MONS, Harmen ,  STOIT, Axel ,  RONKEN, Eric ,  KAM, VAN DER, Elizabeth ,  FRANKENA, Jurjen

    IPC: C07D265/30 ,  C07D265/32 ,  C07D413/12 ,  C07D419/12 ,  C07D471/04 ,  A61K31/5377 ,  A61P25/04 ,  A61P25/06 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D279/12 ,  C07D417/12 ,  C07D487/04

    CPC classification number: C07D295/15 ,  C07D265/30 ,  C07D265/32 ,  C07D279/12 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07F9/6533

    Abstract: The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO 2 -(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH 3 -O- and the linking group –Y-(CH 2 ) n -X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO 2 -, -CH 2 -O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO 2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH 2 ) 2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH 2 -R5, wherein R5 is -OH, -PO 3 H 2 , -OPO 3 H 2 , -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO 2 -; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

    Abstract translation: 本发明涉及式（I）的（硫代）吗啉衍生物，其中R 1选自氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C） 环烷基，（6-8C）双环烷基，（8-10C）双环基团，各自任选被（1-4C）烷基，苯基，联苯基，萘基取代，各自任选被一个或多个独立地选自卤素，（1- 氨基，二（1-4C）烷基氨基，-SO 2 - （1-4C）烷氧基，被一个或多个氟原子烷基取代的（2-4C）炔基，任选被一个或多个氟原子取代的（1-4C） ） - （1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，被苯氧基取代的苯基 （1-4C）烷基或任选被（1-4C）烷基任意取代的苯基的单环杂环，和任选被取代的（1-4C）烷基的双环杂环， 与（1-4C）烷基; A选自-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C = C-，-CCH 3 -O-和连接基-Y-（CH 2）n X- 其中Y连接到R 1并且选自-O - ， - S - ， - SO - ， - SO 2 - ， - CH 2 -O-，-CO-，-O-CO-，-CO-O-， -CO-NH-，-NH-CO-，-C≡C-和-C = C-; n为1〜10的整数， 并且X连接到亚苯基/吡啶基上，并且选自-O - ， - S - ， - SO - ， - SO 2 - ， - NH，-CO - ， - C = C - 和-C = C- ; 环结构B任选地含有一个氮原子; R2是H，任选被一个或多个氟原子取代的（1-4C）烷基，（1-4C）任选被一个或多个氟原子取代的烷氧基或卤素; 并且R 3是（1-4C）亚烷基-R 5，其中亚烷基可以被（CH 2）2取代以形成环丙基部分或一个或两个卤素原子，或者R 3是（3-6C）亚环烷基-R 5或-CO -CH 2 -R 5，其中R 5是-OH，-PO 3 H 2，-OPO 3 H 2，-COOH，-COO（1-4C）烷基或四唑-5-基; R4是H或（1-4C）烷基; R6是一个或多个独立地选自H，（1-4C）烷基或氧代的取代基; W是-O - ， - S - ， - SO-或-SO 2 - ; 或其药学上可接受的盐，溶剂合物或水合物; 条件是式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉代乙醇或4- [4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂合物或 水合物。 本发明的化合物对S1P受体具有亲和力，可用于治疗，缓解或预防S1P受体介导的疾病和病症。

Patent Agency Ranking